Nilotinib 800 Mg And Imatinib 800 Mg For The Treatment Of Patients With Gastrointestinal Stromal Tumors (Gist) Refractory To Imatinib 400 Mg

NCT00751036 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

94

Enrollment

INDUSTRY

Sponsor class

Conditions

Gastrointestinal Stromal Tumors

Interventions

DRUG: Nilotinib
DRUG: Imatinib

Sponsor

Novartis Pharmaceuticals